• Rakovina Therapeutics posted a Q2 net loss of CAD 1.73 million, narrowing 41% from Q2 2025.
• R&D expense fell to CAD 1.13 million, on lower contract research and consulting costs amid higher chemistry and AI activity.
• G&A expense dropped 63% to CAD 450,695, extending a second straight quarter of more than 60% year-over-year cuts.
• Cash totaled CAD 200,115 with a working capital deficit of CAD 2.13 million at June 30.
• After quarter-end, it closed an upsized non-brokered private placement raising CAD 1.99 million; CEO Kim Oishi emphasized non-dilutive financing focus.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rakovina Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608311900PRIMZONEFULLFEED9819021) on August 31, 2026, and is solely responsible for the information contained therein.